Tyche Industries Share Price & Earnings Call Analysis

Financials of Tyche Industries

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Tyche Industries

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +25.2917.0516.0422.2214.2015.5220.5417.7512.3712.7014.1610.5816.20
Expenses +20.1314.2512.9117.3912.3212.9015.8212.9212.5510.7614.299.4916.87
Operating Profit5.162.803.134.831.882.624.724.83-0.181.94-0.131.09-0.67
OPM %20.40%16.42%19.51%21.74%13.24%16.88%22.98%27.21%-1.46%15.28%-0.92%10.30%-4.14%
Other Income +0.941.291.531.511.591.521.142.042.011.772.651.852.96
Interest0.000.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation0.480.460.470.480.540.490.490.500.500.450.470.480.59
Profit before tax5.623.634.195.862.933.655.376.371.333.262.052.461.70
Tax %27.05%25.07%25.30%26.79%28.67%24.93%25.51%25.75%28.57%25.46%25.85%26.02%31.76%
Net Profit +4.102.713.144.292.102.733.994.740.942.431.521.821.15
EPS in Rs4.002.643.064.192.052.663.894.620.922.371.481.781.12

Financials of Tyche Industries

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +63.8654.0842.6151.6053.9573.7078.2462.2775.3969.5165.4753.63
Expenses +56.8051.1636.6242.5744.7852.3153.5251.3059.2456.8654.1951.39
Operating Profit7.062.925.999.039.1721.3924.7210.9716.1512.6511.282.24
OPM %11.06%5.40%14.06%17.50%17.00%29.02%31.60%17.62%21.42%18.20%17.23%4.18%
Other Income +0.251.681.891.692.523.683.753.464.715.927.429.22
Interest1.110.290.080.010.000.000.010.000.000.000.000.00
Depreciation3.341.761.871.851.841.741.721.791.771.941.992.00
Profit before tax2.862.555.938.869.8523.3326.7412.6419.0916.6316.719.46
Tax %32.87%3.53%48.06%33.86%27.41%24.73%25.24%26.11%25.72%26.40%25.73%26.74%
Net Profit +1.932.473.085.867.1517.5619.989.3314.1712.2412.416.94
EPS in Rs1.882.413.005.726.9817.1319.499.1013.8211.9412.116.77
Dividend Payout %26.50%20.71%16.61%8.75%7.17%0.00%5.13%16.48%0.00%20.94%24.78%0.00%

Financials of Tyche Industries

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital10.2310.2310.2310.2510.2510.2510.2510.2510.2510.2510.2510.25
Reserves33.5635.3637.6642.8850.0266.9385.7293.97106.51116.49126.46130.23
Borrowings +8.6810.830.000.070.040.000.000.000.000.000.000.00
Other Liabilities +11.5111.0113.1013.5213.7017.5220.9816.0519.957.9510.697.56
Total Liabilities63.9867.4360.9966.7274.0194.70116.95120.27136.71134.69147.40148.04
Fixed Assets +28.9828.4026.5719.8419.1517.6717.9316.6316.6117.9016.4818.88
CWIP0.380.330.330.000.000.000.530.000.000.000.160.00
Investments0.000.000.000.000.000.000.000.000.000.000.000.00
Other Assets +34.6238.7034.0946.8854.8677.0398.49103.64120.10116.79130.76129.16
Total Assets63.9867.4360.9966.7274.0194.70116.95120.27136.71134.69147.40148.04

Financials of Tyche Industries

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +2.3111.9611.375.043.7515.2115.454.466.437.718.54
Cash from Investing Activity +-0.98-1.340.606.290.632.040.423.16-3.123.94-0.62
Cash from Financing Activity +-3.241.59-10.59-0.60-0.07-0.62-1.02-1.02-1.54-2.05-2.56
Net Cash Flow-1.9012.201.3810.724.3116.6314.856.591.779.615.37
Free Cash Flow1.3310.8211.3310.252.6114.9512.954.584.684.487.84
CFO/OP33%410%190%56%41%71%62%41%40%61%76%

Financials of Tyche Industries

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days90.65106.7181.1268.0568.8164.0479.9196.25106.90100.4095.45132.99
Inventory Days138.2667.7683.6885.37122.85121.71148.08148.32195.21157.11244.61149.93
Days Payable75.6992.82130.5086.8195.7991.4193.0477.86134.4947.9185.2637.78
Cash Conversion Cycle153.2281.6534.3066.6195.8794.34134.95166.71167.62209.60254.79245.13
Working Capital Days77.3921.4660.4866.6386.5377.1182.76121.22128.74144.30150.86177.43
ROCE %7.37%5.22%11.52%17.55%17.36%33.92%32.04%13.32%17.39%13.66%12.67%6.83%

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd